

Brief Biosketch 2021

Gunnar Saeter, M.D., Ph.D.

Year of birth: 1954. Nationality: Norwegian.

Board Certified in Medical Oncology and Radiotherapy (1990).

Current appointments:

Senior Advisor, Oslo University Hospital Comprehensive Cancer Centre.

Professor Emeritus, Institute for Clinical Medicine, University of Oslo.

Board Member, OECI.

Board Member, OECI Accreditation and Designation Programme

Audit Chair, OECI Accreditation and Designation Programme

Member of the Advisory Board, RCSI University of Medicine and Health Sciences, Dublin, Ireland

Member of the Scientific Advisory Board, National Institute of Oncology CCC, Budapest, Hungary

Previous Appointments:

- Consultant Medical Oncologist and Radiotherapist and Section Head, The Norwegian Radium Hospital, Oslo (1993-2000)
- Head, Department of Medical Oncology, The Norwegian Radium Hospital, Oslo (2000-2006)
Chief Physician and Medical Director, Ullevål University Hospital, Oslo (2006-2009)
Global Director of Scientific Affairs, Merck Inc., USA (2009-2013)
- Director, Institute for Cancer Research, Oslo University Hospital (2013-2016)
- Head of Research, Division of Cancer Medicine and OUH Comprehensive Cancer Centre (2016-2020).
- Professor, Institute for Clinical Medicine, University of Oslo (2013-2020)
Board member, Oslo Cancer Cluster Innovation Park (2008-2009 and 2014-2017).
- Secretary and Clinical Research Coordinator, The Scandinavian Sarcoma Group (1988-2000).
- European Society for Medical Oncology (ESMO). Faculty Member 2004-2006.
- ECCO Oncopolicy Committee member from 2016 – 2019.
- Scientific Committee member for ECCO Congresses 2017 and 2018.
- Expert Evaluator for applications to the EU 6th Framework Program. Assigned both project proposal evaluations and mid-term reviews.
- Expert evaluator for the INCA SIRIC integrated research program in France, 2018.

Own Research:

- Fields of particular interest: Sarcomas, liver carcinogenesis, translational and clinical research management, and the continuum and transition from basic through translational and clinical research to innovation.
- 92 full scientific papers listed in PubMed.
- 32 other publications including reviews, book chapters, monographs and popular papers (abstracts not included).
- H-index 30.
- Mentor for 6 completed Ph.D. degrees.
Opponent at 5 Ph.D. dissertations at the University of Lund, Sweden and The University of Oslo.

Innovation:

Initiator and leader of the development a novel IT application for dosage, ordination, pharmacy production, administration, reporting and quality assurance of chemotherapy. The application “Cytodose” has been commercialized and is in use in multiple cancer centres in Norway and Sweden.